William Tillett is a consultant rheumatologist at the Royal National Hospital for Rheumatic Diseases and senior lecturer in the department of pharmacy and pharmacology at the University of Bath, UK.
His current research interests centre on precision medicine in psoriatic arthritis (clinical, radiographic and patient reported outcome). He is the Principle Investigator or Co-Investigator on a variety of clinical commercial and Investigator initiated studies including an NIHR programme grant ‘PROMT’ to improve the detection and assessment of psoriatic arthritis. He currently or has held grants with Abbvie, Celgene, Eli Lilly, Janssen and the NHS to better characterise the patterns and evolution of disease over time and the effect of treatment. He was the UK PI on the Abbvie Control RCT of Adalimumab vs dose escalation of Methotrexte in PsA.